Skip to main content
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Cloudy with a chance of platelets: forecasting chronic ITP.
A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice.
Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.
Therapy by omission: observation as a strategy in JMML.
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
Venous Thromboembolism in Individuals with Sickle Cell Disease- a Retrospective Review of This Understudied Problem
Primary Care Screening for Von Willebrand Disease in African American Adolescents with Heavy Menstrual Bleeding